Merck KGaA Profit Beats Estimates on Cost-Cutting

May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)

Twitter: Bloomberg West (Full Show 02/05)
20:17 - Full episode of "Bloomberg West." Guests: 10x Management Co-Founder Rishon Blumberg, “The Industries of the Future” Author Alec Ross and Death Wish Coffee Founder Michael Brown. (Source: Bloomberg)
  • Bloomberg Best: Mark Hurd
  • Will Mayer’s Turnaround Plan Work for Yahoo?
  • U.S. Stocks Tumble: What'd You Miss? (Full Show 02/05)